 The Deal Pipeline | Abbott to acquire Action Pharma's investigational compound, AP214 for ... pharmabiz.com Abbott has two investigational treatments in development for chronic kidney disease (CKD). Bardoxolone, a first-in-class anti-oxidant inflammation modulator that activates Nrf2, a pathway involved in the progression of CKD, is in phase III development ... Abbott Pays Action $110M for Global Rights to Phase II-Stage Acute Kidney ... Zealand Pharma Signs Licensing Agreement With Abbott for the Further Clinical ... Abbott hits the sweet spot, pays $110M cash for PhIIb drug |
